Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 20Endometrial Hyperplasia 7Overweight 2Obesity 2Turcot syndrome 1Squamous Intraepithelial Lesions 1Recurrence 1Neoplasms 1Mesothelioma, Malignant 1Infertility 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

Hysterectomy 2ipatasertib 1entinostat 1Telemedicine 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Megestrol Acetate × Gynecologic × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡